KALV R&D to Revenue
Kalvista Pharmaceuticals Inc · R&D to Revenue
KALV R&D to Revenue
Latest reported14.77%period ending
KALV Quarterly R&D/Revenue (280.40% → 14.77%)
Latest values, visible window
High-resolution chart · PNG
KALV r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 14.7676% | |
| 30.3942% | |
| 87.5913% | |
| 1,063.2539% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 248.0387% | |
| 712.3018% | |
| 249.7194% | |
| 287.5037% | |
| 380.6904% | |
| 196.6581% | |
| 140.8441% | |
| 224.7445% | |
| 120.9091% | |
| 195.1094% | |
| 386.9565% | |
| 3,620.8333% | |
| 2,628.0702% | |
| 1,346.371% | |
| 0% | |
| 4,742.8571% | |
| 50,457.1429% | |
| 53,250% | |
| 50,471.4286% | |
| 64,342.8571% | |
| 55,742.8571% | |
| 37,887.5% | |
| 20,880% | |
| 35,000% | |
| 23,750% | |
| 280.402% |